» Articles » PMID: 15024077

Translocation Products in Acute Myeloid Leukemia Activate the Wnt Signaling Pathway in Hematopoietic Cells

Abstract

The acute myeloid leukemia (AML)-associated translocation products AML1-ETO, PML-retinoic acid receptor alpha (RARalpha), and PLZF-RARalpha encode aberrant transcription factors. Several lines of evidence suggest similar pathogenetic mechanisms for these fusion proteins. We used high-density oligonucleotide arrays to identify shared target genes in inducibly transfected U937 cells expressing AML1-ETO, PML-RARalpha, or PLZF-RARalpha. All three fusion proteins significantly repressed the expression of 38 genes and induced the expression of 14 genes. Several of the regulated genes were associated with Wnt signaling. One of these, plakoglobin (gamma-catenin), was induced on the mRNA and protein level by all three fusion proteins. In addition, primary AML blasts carrying one of the fusion proteins significantly overexpressed plakoglobin. The plakoglobin promoter was cloned and shown to be induced by AML1-ETO, with promoter activation depending on the corepressor and histone deacetylase binding domains. The induction of plakoglobin by AML fusion proteins led to downstream signaling and transactivation of TCF- and LEF-dependent promoters, including the c-myc promoter, which was found to be bound by plakoglobin in vivo after AML1-ETO expression. beta-Catenin protein levels and TCF and LEF target genes such as c-myc and cyclin D1 were found to be induced by the fusion proteins. On the functional level, a dominant negative TCF inhibited colony growth of AML1-ETO-positive Kasumi cells, whereas plakoglobin transfection into myeloid 32D cells enhanced proliferation and clonal growth. Injection of plakoglobin-expressing 32D cells into syngeneic mice accelerated the development of leukemia. Transduction of plakoglobin into primitive murine hematopoietic progenitor cells preserved the immature phenotype during colony growth, suggesting enhanced self-renewal. These data provide evidence that activation of Wnt signaling is a common feature of several balanced translocations in AML.

Citing Articles

Secreted Frizzled-Related Protein 1a regulates hematopoietic development in a dose-dependent manner.

Ide A, Carpenter K, Elaswad M, Opria K, Marcellin K, Gilliland C bioRxiv. 2025; .

PMID: 39829913 PMC: 11741364. DOI: 10.1101/2025.01.10.632371.


Homoharringtonine may help improve the outcomes of venetoclax and azacitidine in AML1-ETO positive acute myeloid leukemia.

Yin Z, Yao Z, Chen D, Zhang Y, Weng G, Du X J Cancer Res Clin Oncol. 2024; 150(7):336.

PMID: 38969948 PMC: 11226518. DOI: 10.1007/s00432-024-05861-9.


Design, Synthesis, and Anti-Leukemic Evaluation of a Series of Dianilinopyrimidines by Regulating the Ras/Raf/MEK/ERK and STAT3/c-Myc Pathways.

Wang C, Wang B, Mou Y, Liu X, Chen Q, Pu W Molecules. 2024; 29(7).

PMID: 38611876 PMC: 11013136. DOI: 10.3390/molecules29071597.


The multi-CDK inhibitor dinaciclib reverses bromo- and extra-terminal domain (BET) inhibitor resistance in acute myeloid leukemia via inhibition of Wnt/β-catenin signaling.

Marr A, Halpin M, Corbin D, Asemelash Y, Sher S, Gordon B Exp Hematol Oncol. 2024; 13(1):27.

PMID: 38438856 PMC: 10913666. DOI: 10.1186/s40164-024-00483-w.


Lactate Utilization Enables Metabolic Escape to Confer Resistance to BET Inhibition in Acute Myeloid Leukemia.

Monteith A, Ramsey H, Silver A, Brown D, Greenwood D, Smith B Cancer Res. 2024; 84(7):1101-1114.

PMID: 38285895 PMC: 10984779. DOI: 10.1158/0008-5472.CAN-23-0291.


References
1.
Yuan Y, Zhou L, Miyamoto T, Iwasaki H, Harakawa N, Hetherington C . AML1-ETO expression is directly involved in the development of acute myeloid leukemia in the presence of additional mutations. Proc Natl Acad Sci U S A. 2001; 98(18):10398-403. PMC: 56972. DOI: 10.1073/pnas.171321298. View

2.
Muller-Tidow C, Metzger R, Kugler K, Diederichs S, Idos G, Thomas M . Cyclin E is the only cyclin-dependent kinase 2-associated cyclin that predicts metastasis and survival in early stage non-small cell lung cancer. Cancer Res. 2001; 61(2):647-53. View

3.
Weinmann A, Bartley S, Zhang T, Zhang M, Farnham P . Use of chromatin immunoprecipitation to clone novel E2F target promoters. Mol Cell Biol. 2001; 21(20):6820-32. PMC: 99859. DOI: 10.1128/MCB.21.20.6820-6832.2001. View

4.
Licht J . AML1 and the AML1-ETO fusion protein in the pathogenesis of t(8;21) AML. Oncogene. 2001; 20(40):5660-79. DOI: 10.1038/sj.onc.1204593. View

5.
Potter E, Braun S, Lehmann U, Brabant G . Molecular cloning of a functional promoter of the human plakoglobin gene. Eur J Endocrinol. 2001; 145(5):625-33. DOI: 10.1530/eje.0.1450625. View